Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 12
• Langue: English

Extrait

Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences

PR Newswire MOUNTAIN VIEW, California, July 17, 2012

- Its pioneering LAESI DP-1000 Direct Ionization System is set to be a key enabling technology for breakthroughs in research, diagnostics and medicine MOUNTAIN VIEW, California,July 17, 2012/PRNewswire/ -- Based on its recent analysis of the bioanalytics market, Frost & Sullivan recognizes Protea Biosciences Group, Inc. with the 2012 North American Frost & Sullivan Award for New Product Innovation for the LAESI DP-1000. This instrument is the first to allowin vivomass spectrometry (MS) applications and positions Protea at the forefront of technology-enablers for novel scientific discoveries. Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry. Protea—which provides bioanalytical products and services for the life sciences and biochemical markets—secured an exclusive worldwide licensing agreement with George Washington University for commercial rights to Laser Ablation Electrospray Ionization (LAESI) MS technology inSeptember 2008. This technology enables the direct identification of molecules of interest in biological samples and provides information on their distribution profile. In 2012, the firm launched the LAESI DP-1000 Direct Ionization System as both an off-the-shelf instrument and a service, allowing a broad base of the scientific community to gain access to the technology. "With an expanding line of service offerings and growing awareness of the LAESI DP-1000, Protea Biosciences has emerged as a significant player in bioanalytics and an enabler of major scientific breakthroughs," said Frost & Sullivan Sr. Industry Analyst Christi Bird. "The LAESI DP-1000 system greatly improves the efficiency of biological investigations, allowing scientists to better understand the mechanics of a pathology and the effects of drug and target interaction." Furthermore, with the capability to ionize native samples, the LAESI DP-1000 analyzes living cells and tissues in their natural environment, which provides precise and significant data on biological states. This allows researchers to accurately answer biological questions concerning the molecular events of live cells and tissues, a truly market-changing capability. These novel applications make the LAESI DP-1000 a highly innovative and powerful instrument. The speed of data acquisition using the LAESI platform workflow allows for both spatial and dynamic mapping of biomolecules. With applications in the fields of pharmaceutical and biological research, surgical and molecular pathology, clinical diagnostics, chemical and biological defense, forensics, and food safety, Protea is primed for significant growth as researchers become familiar with the benefits of LAESI-MS technolo.